How does PARP inhibition work, and what does it do in ovarian cancer cells?
Olaparib inhibits PARP enzymes involved in repairing single-strand DNA breaks. When PARP is blocked, DNA damage accumulates, and cancer cells become more likely to die—especially cells that already struggle to repair DNA due to defects in homologous recombination (most commonly from BRCA1 or BRCA2 mutations). This creates a form of “synthetic lethality,” where the combination of impaired DNA repair plus PARP inhibition is lethal to the tumor cell while being less harmful to normal cells [1].
In ovarian cancer, this mechanism is most relevant to tumors with homologous recombination deficiency (HRD). HRD can come from BRCA1/2 mutations and also from other alterations that impair the homologous recombination repair pathway. In these settings, blocking PARP shifts replication-associated DNA damage toward cell death [1].
What happens after olaparib blocks PARP—why do tumors shrink or stop growing?
By preventing repair of single-strand DNA breaks, olaparib drives ongoing DNA damage during cell division. Tumor cells may undergo apoptosis (programmed cell death) and other lethal replication failures when accumulated DNA damage becomes too extensive. Clinically, that translates to reduced tumor viability and slower tumor growth, which is why PARP inhibitors are used in ovarian cancer treatment strategies [1].
Why is olaparib especially effective in BRCA-mutated or HRD ovarian cancer?
BRCA1/2 are key components of homologous recombination. If BRCA1/2 are mutated (or homologous recombination is otherwise defective), the cell cannot accurately repair double-strand DNA breaks that arise when replication proceeds under DNA damage stress. PARP inhibition increases the burden of DNA lesions that turn into replication-associated double-strand breaks, which BRCA/HRD-defective cells cannot resolve effectively [1].
How does PARP inhibition help in recurrent ovarian cancer and treatment maintenance?
In practice, PARP inhibitors like olaparib are used to control disease and delay progression in ovarian cancer, including settings where tumors have returned after initial platinum-based chemotherapy. The underlying reason is the same: recurrent tumors often retain vulnerabilities related to HRD and DNA repair impairment, so continued PARP blockade can keep promoting lethal DNA damage in residual cancer cells [1].
Are there ovarian cancer cases where PARP inhibitors work less well?
If a tumor is proficient in homologous recombination (no meaningful HRD and no BRCA/HRD-driven vulnerability), the cancer cell can often repair the DNA lesions created when PARP is inhibited. That can reduce the impact of olaparib’s mechanism and lead to less benefit compared with HRD/BRCA-mutated tumors [1].
Tumors can also become resistant over time by restoring homologous recombination capacity or altering how PARP inhibition affects repair and replication stress. Those resistance processes reduce the synthetic-lethality effect that olaparib depends on [1].
What side effects are connected to PARP inhibition’s mechanism?
Because PARP enzymes also support DNA repair in normal cells, PARP inhibitors commonly cause blood-related toxicities (for example, anemia, neutropenia, or thrombocytopenia). These reflect stress on rapidly dividing cells and DNA repair demands outside the tumor as well as the overall effects of persistent DNA damage signaling when PARP is blocked [1].
What to consider when asking whether a patient’s tumor should respond
Response to olaparib is most tied to whether the ovarian cancer shows a DNA repair vulnerability (HRD), especially BRCA1/2 mutations. Testing and clinical selection determine who is most likely to benefit from a PARP inhibitor based on that DNA repair mechanism [1].
---
Sources
- https://www.cancer.gov/publications/dictionaries/cancer-drug/def/olaparib